Investors

Welcome to our Investor Centre

Please click on the Profiles below to see more details on our other clients:

All of the information contained within this website has been compiled from sources believed to be reliable, but no warranty, expressed or implied, is given that the information is complete or accurate or that it is fit for a particular purpose. All such warranties are expressly disclaimed and excluded. Any opinions, recommendations and forecasts referred to are not those of Walbrook PR Limited but are expressly those of third parties, such as investment analysts and financial journalists. Such opinions, recommendations and forecasts may have been superseded and thus may not necessarily be the current opinions, recommendations and forecasts of the relevant analyst/broker. None of the content of this website should be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities of any listed Company mentioned or featured herein as it is for information only. Any recommendations referred to by third parties do not necessarily imply the suitability of particular securities for individual situations. The value of securities and the income from them may fluctuate. It should be remembered that past performance is not necessarily a guide to future performance. You are strongly advised to seek guidance from a professional investment adviser before entering into any contract to buy or sell any security featured herein. By reading this disclaimer, and ticking the box below, you confirm that you accept and understand its content, and that you shall not hold Walbrook PR Limited, its directors and staff nor any of its subsidiaries or connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities.

Shield Therapeutics plc

Company Profile

Company website
Sector
Pharmaceuticals & Biotechnology (Pharmaceuticals)
Description

Shield is a commercial stage pharmaceutical company focused on the commercialisation of Accrufer®/Feraccru® (ferric maltol), an innovative oral iron therapy for iron deficiency differentiated from other irons by its efficacy, broad label and well-tolerated formulation. The Group has launched Accrufer® in the US with an exclusive, multi-year collaboration agreement with Viatris, Inc. Feraccru® is commercialised in the UK and European Union by Norgine B.V., that also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

Investor Access

31 Oct
Event information

Management will be hosting a live online presentation relating to the Q3 trading update on Thursday 31 October 2024.

Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
Venue
Online
Time

Thursday 31 October 2024 at 2pm GMT

Financial Calendar
 Event  Date
Year End 31 December
Half  Year End 30 June
Preliminary Results* May
Interim Results* September
AGM* June

* Months based on previous announcements of this kind